NEW YORK (GenomeWeb News) – IntelligentMDx said today that it has entered into a development and licensing agreement to design, develop, and manufacture CE-marked and US Food and Drug Administration-cleared diagnostic tests for use on Qiagen's QIAsymphony RGQ platform.

IMDx did not disclose the assays, but said they will be incorporated into Qiagen's growing portfolio of molecular diagnostic assays and be distributed worldwide by Qiagen. Qiagen also retained the rights to manufacture the assays pursuant to volume considerations, IMDx said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.